Innovative Buprenorphine Initiation Strategies

Sunday, April 27, 2025

10:15 AM – 11:30 AM

Presenter(s)

Melissa B. Weimer, DO, MCR, DFASAM

Associate Professor of Medicine
Yale School of Medicine
New Haven, Connecticut
AH

Andrew A. Herring, MD

Director, California Bridge
Highland Hospital
Oakland, California
Pouya Azar, MD, FRCPC, DABAM

Addiction Medicine Physician
Vancouver General Hospital & UBC
Vancouver, British Columbia
David Wolinsky, MD

Assistant Professor
Department of Psychiatry and Behavioral Sciences at the Johns Hopkins School of Medicine
Baltimore, Maryland

This session will present cutting edge buprenorphine initiation approaches in a variety of settings. Topics discussed include naloxone-facilitated buprenorphine initiation, low dose buprenorphine initiation with methadone continuation, and use of XR buprenorphine for buprenorphine initiation.

Learning Objectives:

Learners will be able to:

Describe the unique pharmacology of fentanyl and its analogues
Describe the current evidence regarding buprenorphine and methadone initiation in people using illicit fentanyl.
Discuss the rationale and potential risks and benefits of innovative OUD initiation strategies

Disclosure(s):

Melissa B. Weimer, DO, MCR, DFASAM: No financial relationships to disclose

Pouya Azar, MD, FRCPC, DABAM: Indivior: Consultant/Advisory Board (Terminated, October 5, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 5, 2024)

David Wolinsky, MD: No financial relationships to disclose